Bank of New York Mellon Corp raised its stake in shares of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) by 4.9% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 571,639 shares of the specialty pharmaceutical company’s stock after buying an additional 26,786 shares during the period. Bank of New York Mellon Corp owned about 1.53% of Foamix Pharmaceuticals worth $3,172,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in FOMX. AXA raised its stake in shares of Foamix Pharmaceuticals by 14.1% during the 2nd quarter. AXA now owns 942,735 shares of the specialty pharmaceutical company’s stock valued at $4,374,000 after buying an additional 116,298 shares during the last quarter. PDT Partners LLC purchased a new position in shares of Foamix Pharmaceuticals during the 2nd quarter valued at about $304,000. DAFNA Capital Management LLC raised its stake in shares of Foamix Pharmaceuticals by 9.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 355,667 shares of the specialty pharmaceutical company’s stock valued at $1,650,000 after buying an additional 30,000 shares during the last quarter. Finally, UBS Asset Management Americas Inc. raised its stake in shares of Foamix Pharmaceuticals by 1.6% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 106,312 shares of the specialty pharmaceutical company’s stock valued at $493,000 after buying an additional 1,633 shares during the last quarter. Institutional investors and hedge funds own 57.43% of the company’s stock.
Shares of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) opened at $6.64 on Friday. Foamix Pharmaceuticals Ltd has a 12-month low of $4.03 and a 12-month high of $11.27. The company has a market capitalization of $236.20, a PE ratio of -4.12 and a beta of 1.62.
Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.47) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.03). Foamix Pharmaceuticals had a negative net margin of 1,439.32% and a negative return on equity of 54.81%. The business had revenue of $0.90 million for the quarter, compared to analyst estimates of $0.90 million. During the same quarter last year, the business earned ($0.19) earnings per share. Foamix Pharmaceuticals’s revenue was down 64.6% on a year-over-year basis. research analysts forecast that Foamix Pharmaceuticals Ltd will post -0.95 EPS for the current year.
A number of equities analysts have weighed in on the company. Guggenheim reiterated a “buy” rating and set a $8.00 price objective on shares of Foamix Pharmaceuticals in a research note on Thursday, December 14th. Zacks Investment Research upgraded Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th. Finally, HC Wainwright set a $12.00 price objective on Foamix Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 29th.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.